{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}],"title":"CR"},{"measurements":[{"groupId":"OG000","value":"13"}],"title":"CRi"},{"measurements":[{"groupId":"OG000","value":"3"}],"title":"Partial Response (PR)"},{"measurements":[{"groupId":"OG000","value":"2"}],"title":"No Response (NR)"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"}],"units":"Participants"}],"description":"Proportion of participants achieving CR and proportion of participants achieving CRi by the end of one or two courses of CPX-351 Complete morphologic remission response (CR) is defined as less than 5% blasts without Auer rods by morphological evaluation of the bone marrow (M1 marrow). Patients in morphologic CR without hematological recovery (white cell blood count ≥ 1.0 x 10\\^9/L, unsupported platelet count ≥ 30.0 x 10\\^9/L and absolute neutrophil count ≥ 0.3 x 10\\^9/L) are classified as morphological CR and incomplete recovery (CRi) of absolute neutrophil, white blood cell, and/or platelet counts.","groups":[{"description":"All eligible patients will receive up to 2 cycles of CPX-351 for remission induction.","id":"OG000","title":"CPX-351 (Vyxeos)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Participants who received one or 2 course of CPX-351.","reportingStatus":"POSTED","timeFrame":"Day 22 of Cycle 1 and day 22-28 of Cycle 2","title":"Complete Remission (CR) and Complete Remission With Incomplete Peripheral Blood Recovery (CRi) Rate","type":"PRIMARY","unitOfMeasure":"Participants"}